Mostrar el registro sencillo del ítem

dc.contributor.authorGonzález Rodríguez, María
dc.contributor.authorAit Edjoudi, D.
dc.contributor.authorCordero Barreal, Alfonso
dc.contributor.authorRuiz Fernández, Clara
dc.contributor.authorFarrag, M.
dc.contributor.authorGonzález-Rodríguez, B.
dc.contributor.authorLago Paz, Francisca 
dc.contributor.authorCapuozzo, M.
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.authorMera Varela, Antonio 
dc.contributor.authorPino Mínguez, Jesús 
dc.contributor.authorFarrag, Y.
dc.contributor.authorGualillo, Oreste
dc.date.accessioned2025-08-26T11:00:06Z
dc.date.available2025-08-26T11:00:06Z
dc.date.issued2022
dc.identifier.citationGonzález-Rodríguez M, Ait Edjoudi D, Cordero Barreal A, Ruiz-Fernández C, Farrag M, González-Rodríguez B, et al. Progranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review. Pharmaceuticals. 2022;15(12).
dc.identifier.issn1424-8247
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/63b996e14386723d2da37900*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20781
dc.description.abstractProgranulin (PGRN) is a glycoprotein formed by 593 amino acids encoded by the GRN gene. It has an important role in immunity and inflammatory response, as well as in tissue recovery. Its role in musculoskeletal inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and intervertebral disc degeneration disease (IVDD), is, nowadays, an important target to investigate. The objective of this review is to systematically sum up all the recent findings concerning PGRN as a target in the development and resolution of the inflammatory diseases. PubMed was examined with the terms combinations (Progranulin) AND (Lupus Erythematosus, Systemic), (Progranulin) AND (Arthritis, Rheumatoid), and (Progranulin) AND (Intervertebral Disc Degeneration). PubMed was examined with the terms combinations (Atsttrin) AND (Lupus Erythematosus, Systemic), (Atsttrin) AND (Arthritis, Rheumatoid), and (Atsttrin) AND (Intervertebral Disc Degeneration). Moreover, research through Web of Science was performed searching the same items. The inclusion criteria were: studies whose main topic were progranulin, or atsttrin, with emphasis on the three selected diseases. On the other hand, the exclusion criteria were studies that only focused on diseases not related to RA, lupus or IVDD, in addition to the previous published literature reviews. Since few results were obtained, we did not filter by year. The records assessed for eligibility were 23, including all the studies with the information in state of art of progranulin and its capability to be a potential target or treatment for each one of the selected diseases. As these results are descriptive and not clinical trials, we did not perform risk of bias methods. Within these results, many studies have shown an anti-inflammatory activity of PGRN in RA. PGRN levels in serum and synovial fluids in RA patients were reported higher than controls. On the other hand, serum levels were directly correlated with SLE disease activity index, suggesting an important role of PGRN as a player in the progression of inflammatory diseases and a therapeutical approach for the recovery. This review has some limitations due to the small number of studies in this regard; therefore, we highlight the importance and the necessity of further investigation. No external funding was implicated in this systematical review.en
dc.description.sponsorshipO.G. and F.L. are Staff Personnel (I3SNS Stable Researcher) of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff contract (ISCIII)/SERGAS). O.G. and M.A.G.G. are members of RICORS Programme, RD21/0002/0025 via ISCIII and FEDER. F.L. is a member of Centro de Investigacion Biomedica en Red de Enfermedades Cardiovasculares (CIBERCV). The work of O.G. and J.P. (PI20/00902), and F.L. (PI21/01145 and CB16/11/00226) is funded by ISCIII and FEDER. O.G. is a beneficiary of a project funded by the Research Executive Agency of the European Union in the framework of MSCA- RISE Action of the H2020 Programme (project number 734899). O.G. is the beneficiary of a grant funded by Xunta de Galicia, Conselleria de Educacion, Universidade e Formacion Profesional and Conselleria de Economia, Emprego e Industria (GAIN) (GPC IN607B2022/03). M.G-R. is a recipient of predoctoral contract funded by Xunta de Galicia (IN606A-2020/010). ISCIII and FEDER funded through a predoctoral research scholar to C.R-F. (Exp.18/00188). A.C.B. is a recipient of a predoctoral contract funded by Secretaria de Estado de Universidades, Investigacion, Desarrollo e Innovacion, Ministerio de Universidades (FPU2018-04165). Y.F is a 'Sara Borrell' researcher funded by ISCIII and FEDER [CD21/00042]. The funders were not involved in study design, data collection and analysis, decision to publish or manuscript preparation.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleProgranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review*
dc.typeReviewen
dc.authorsophosGonzález-Rodríguez, O. M.
dc.authorsophosAit Edjoudi, D.
dc.authorsophosCordero Barreal, A.
dc.authorsophosRuiz-Fernández, C.
dc.authorsophosFarrag, M.
dc.authorsophosGonzález-Rodríguez, B.
dc.authorsophosLago, F.
dc.authorsophosCapuozzo, M.
dc.authorsophosGonzalez-Gay, M. A.
dc.authorsophosMera Varela, A.
dc.authorsophosPino, J.
dc.authorsophosFarrag, Y.
dc.authorsophosGualillo
dc.identifier.doi10.3390/ph15121544
dc.identifier.sophos63b996e14386723d2da37900
dc.issue.number12
dc.journal.titlePharmaceuticals*
dc.relation.projectIDISCIII [RD21/0002/0025, PI20/00902, PI21/01145, CB16/11/00226]; FEDER [Exp.18/00188, CD21/00042]; Research Executive Agency of the European Union in the framework of MSCA- RISE Action of the H2020 Programme [734899]; Xunta de Galicia, Conselleria de Educacion, Universidade e Formacion Profesional and Conselleria de Economia, Emprego e Industria (GAIN) [GPC IN607B2022/03]; Xunta de Galicia [IN606A-2020/010]; Secretaria de Estado de Universidades, Investigacion, Desarrollo e Innovacion, Ministerio de Universidades [FPU2018-04165]
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/15/12/1544/pdf?version=1671009872;https://mdpi-res.com/d_attachment/pharmaceuticals/pharmaceuticals-15-01544/article_deploy/pharmaceuticals-15-01544-v2.pdf?version=1671009872es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo de Revisiónes
dc.volume.number15


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional